Thinly traded nano cap Opiant Pharmaceuticals (NASDAQ:OPNT) is up 73% premarket on increased volume on the heels of Emergent BioSolutions’ announced acquisition of Adapt Pharma for up to $735M.
Adapt Pharma markets Opiant’s NARCAN Nasal Spray for the emergency treatment of opioid overdose. Opiant receives 90% of the royalties and milestone payments for the product.
Previously: Emergent Bio to acquire Adapt Pharma for up to $735M (Aug. 28)
Previously: Opiant to book $11.7M in Narcan-related income in 2017; shares up 11% premarket (Feb. 8)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.